Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer’s Go-It-Alone Approach Nets $1.95bn COVID Vaccine Order From US Government

Executive Summary

Supply agreement with the Health and Human Services Department and the Department of Defense reflects a profitable per dose price of $19.50 for an initial batch of 100 million doses of the vaccine candidate, pending FDA authorization or approval.

You may also be interested in...



Pfizer’s Arms-Length Attitude Toward Operation Warp Speed: Two Views On How It Worked

Pfizer CEO Albert Bourla and HHS deputy chief of staff Paul Mango offer their perspectives in separate interviews promoting new books about the campaign to develop vaccines against COVID-19.

Can China Convince World With Its Fast, Cheap COVID Vaccines?

As China gears up to the possible launch of its first vaccines against the coronavirus, supported by clearer regulations, many see the candidates as promising and cost-effective, although they may need more convincing data to be widely adopted. Relatively low projected per dose costs are generating interest in trials in multiple countries.

Stepping Up? Pharma’s Early COVID Pricing Decisions May Be Resolving Concerns

Cigna's Steve Miller suggests pharma is taking a responsible approach to pricing during the pandemic in a policy discussion convened by the Institute for Clinical and Economic Review on pricing models for COVID-19 drugs and vaccines.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS142594

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel